Latest disclosed round
Series B (described in source as 'additional financing' - letter not explicit)
- Date
- 2023-09-01
- Amount
- USD 39m
- Sector
- Biotech & techbio
- Companies House
- 10366466
Series B
Sitryx Therapeutics
Immunometabolism (autoimmune/inflammatory disease)
CandidateSeries BOxford
Evidence status
Review retained
- Identity
- Candidate
- Match
- High candidate
- Operating status
- active
- Data origins
- Core directory, Growth Network, Live Chris T D1
Capital network
6 linked investors
Funding record
1 disclosed round
| Date | Stage | Amount | Investors |
|---|---|---|---|
| 2023-09-01 | Series B | $39M / £32M | Oxford Science Enterprises, SV Health Investors, Eli Lilly, Sofinnova Partners, Longwood Fund, GSK |
Traceability
Source trail
Funding and investor claims retain their public-source links. This is a research snapshot, not a live cap table.